These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31297313)

  • 1. Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade.
    Goel S; Sinha RJ; Bhaskar V; Aeron R; Sharma A; Singh V
    Asian J Urol; 2019 Jul; 6(3):222-229. PubMed ID: 31297313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer.
    Yuh BE; Ruel N; Wilson TG; Vogelzang N; Pal SK
    J Urol; 2013 May; 189(5):1682-6. PubMed ID: 23123547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis.
    Ferro M; de Cobelli O; Musi G; Lucarelli G; Terracciano D; Pacella D; Muto T; Porreca A; Busetto GM; Del Giudice F; Soria F; Gontero P; Cantiello F; Damiano R; Crocerossa F; Farhan ARA; Autorino R; Vartolomei MD; Muto M; Marchioni M; Mari A; Scafuri L; Minervini A; Longo N; Chiancone F; Perdona S; De Placido P; Verde A; Catellani M; Luzzago S; Mistretta FA; Ditonno P; Caputo VF; Battaglia M; Zamboni S; Antonelli A; Greco F; Russo GI; Hurle R; Crisan N; Manfredi M; Porpiglia F; Di Lorenzo G; Crocetto F; Buonerba C
    Front Oncol; 2021; 11():651745. PubMed ID: 34046347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial.
    Anari F; O'Neill J; Choi W; Chen DYT; Haseebuddin M; Kutikov A; Dulaimi E; Alpaugh RK; Devarajan K; Greenberg RE; Bilusic M; Wong YN; Viterbo R; Hoffman-Censits JH; Lallas CD; Trabulsi EJ; Smaldone M; Geynisman DM; Zibelman M; Lin J; Kelly WK; Uzzo R; McConkey D; Plimack ER
    Eur Urol Oncol; 2018 May; 1(1):54-60. PubMed ID: 30420974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
    Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
    Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.
    Huo J; Ray-Zack MD; Shan Y; Chamie K; Boorjian SA; Kerr P; Jana B; Freedland SJ; Kamat AM; Mehta HB; Williams SB
    Eur Urol Oncol; 2019 Sep; 2(5):497-504. PubMed ID: 31411998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle-invasive bladder cancer: results from JCOG0209, a randomized phase III study.
    Kitamura H; Hinotsu S; Tsukamoto T; Shibata T; Mizusawa J; Kobayashi T; Miyake M; Nishiyama N; Kojima T; Nishiyama H;
    Jpn J Clin Oncol; 2020 Dec; 50(12):1464-1469. PubMed ID: 32699909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
    Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
    Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience.
    Lemiński A; Kaczmarek K; Byrski T; Słojewski M
    PLoS One; 2021; 16(11):e0259526. PubMed ID: 34731219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Wu T; Wu Y; Chen S; Wu J; Zhu W; Liu H; Chen M; Xu B
    Front Oncol; 2021; 11():678896. PubMed ID: 34900663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
    Culine S; Harter V; Gravis G; Fléchon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Abadie-Lacourtoisie S; Geoffrois L; Fiore FD; Roubaud G; Barthélémy P; Voog E; Emambux S; Serrate C; Saldana C; Nguyen-Tan-Hon T; Loriot Y; Eymard JC; Huillard O; Rolland F; Houédé N; Spano JP; Demery ME; Vieillot S; L'Haridon T; Hilgers W; Allory Y; Pfister C;
    Clin Genitourin Cancer; 2021 Dec; 19(6):554-562. PubMed ID: 34602349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer.
    Lee FC; Harris W; Cheng HH; Shenoi J; Zhao S; Wang J; Champion T; Izard J; Gore JL; Porter M; Yu EY; Wright JL
    Adv Urol; 2013; 2013():317190. PubMed ID: 24382958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    Marcq G; Jarry E; Ouzaid I; Hermieu JF; Henon F; Fantoni JC; Xylinas E
    Ther Adv Urol; 2019; 11():1756287218823678. PubMed ID: 30728860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis.
    Chung DY; Kang DH; Kim JW; Ha JS; Kim DK; Cho KS
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of neoadjuvant chemotherapy in invasive bladder cancer.
    Cam K; Yildirim A; Ozveri H; Turkeri L; Akdas A
    Int Urol Nephrol; 2002; 33(1):49-52. PubMed ID: 12090338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience.
    El-Gehani F; North S; Ghosh S; Venner P
    Can Urol Assoc J; 2014 Mar; 8(3-4):e287-93. PubMed ID: 24839503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
    Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
    Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.